Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (17815)	1/15/1999 8:08:00 PM
From: VLAD	Read Replies (3) \| Respond to of 23519

Food for thought: Most biotechs never made a dime and have never produced a final FDA approved product. Most of these companies depend on relationships with large pharmas to help fund their research. Vivus' research was never funded by large pharma relations. The money came from us investors in their stock sales including two secondary offerings. If LW ever manages to get the partner he needs to work on further negotiations in order to get big pharma money behind research that can produce further intraurethral products. I understand that premature ejaculation is a much larger market than impotence. I do not know what research has actually progressed on this problem but I believe that there are already generic drugs available that can help treat this problem. Perhaps even something as simple as an intraurethrally delivered topical anesthetic would work well by decreasing sensitivity to the penis. Vivus needs to get the ball rolling on applying their intraurethral patent towards premature ejaculation ASAP. Negotiating a deal with a big pharma company to pay an upfront payment and research milestones with a future marketing agreement is another job for LW to earn his 350k on. He probably is counting paper clips now anyway while CS First Boston is negotiating the MUSE partnership.